Thrombosis in cancer patients treated with hematopoietic growth factors - A meta-analysis on behalf of the subcommittee: On haemostasis and malignancy of the scientific and standardization committee of the ISTH

Thrombosis and Haemostasis

Volumn 75, Issue 2, 1996, Pages 368-371

  Barbui, T ^a   Finazzi, G ^a   Grassi, A ^a   Marchioli, R ^b  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR;

ARTICLE; BLOOD VESSEL OCCLUSION; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK; THROMBOGENESIS; THROMBOSIS;

EID: 0029879540     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650276     Document Type: Article

References (33)

1. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471-508.
2. Lindemann A, Rumberger B. Vascular complications in patients treated with granulocyte colony stimulating factor (G-CSF). Eur J Cancer 1993; 16: 2338-9.
3. Conti JA, Scher HI. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorabicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. Cancer 1992; 70: 2699-702.
4. Stephens LC, Haire WD, Schmit-Pokorny K, Kessinger A, Kotulak G. Granulocyte macrophage colony stimulating factor: high incidence of apheresis catheter thrombosis during peripheral stem cell collection. Bone Marrow Transplantation 1993; 11: 51-4.
5. Biesma B, deVries EGE, Willemse PHB, Sluiter WJ, Postmus PE, Limburg PC, Stern AC, Vellenga E. Efficacy and tolerability of recombinant human granulocyte-macrophage colony stimulating factor in patients with chemotherapy-related leukopenia and fever. Eur J Cancer 1990; 26: 932-6.
6. Gorin NC, Coiffier B, Hayat M, Fouillard L, Kuentz M, Flesch M, Colombat P, Boivin P, Slavin S, Lemarié JC, Eugène-Jolchine I, Philip T. Facteur de croissance hématopoiétique (GM-CSF) après autogreffe de moelle osseuse. La Presse Médicale 1993; 22: 109-20.
7. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.
8. Grem JL, McAtee N, Murphy RF, Hamilton JM, Balis F, Steinberg S, Arbuck SG, Setser A, Jordan E, Chen A. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. J Clin Oncol 1994; 12: 560-8.
9. Paccagnella A, Favaretto A, Riccardi A, Danova M, Ghiotto C, Giordano M, Pappagallo G, Comis S, Panozzo M, Chieco Bianchi L, Fiorentino MV. Granulocyte-macrophage colony stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics. Cancer 1993; 72: 697-706.
10. Bukowski RM, Murty S, McLain D, Finke J, Andresen S, Tubbs R, Bauer L, Gibson V, Budd GT, Thomassen MJ. Phase I trial of recombinant granulocyte-macrophage colony stimulating factor in patients with lung cancer: clinical and immunologic effects. J Immunother 1993; 13: 267-74.
11. Miles DW, Fogarty O, Ash CM, Rudd RM, Trask CW, Spiro SG, Gregory WM, Ledermann JA, Souhami RL, Harper PG. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 1994; 12: 77-82.
12. Gridelli C, De Placido S, Pepe R, Incoronato P, Airoma G, Rossi A, Palazzolo G, Bianco AR. Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer. Eur J Cancer 1993; 29A (12): 1729-31.
13. Eguchi K, Etou H, Miyachi S, Morinari H, Nakada K, Noda K, Ohkuni Y, Watanabe K, Yamada Y, Ohe Y, Tamura T, Sasaki Y, Shonkai T, Saijo N. A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer. Eur J Cancer 1994; 30A (2): 188-94.
14. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakawaga K, Hirashima T, Tamanoi M, Nitta T, Yana T, Negoro S, Takifuji N, Takada M. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 1994; 12: 90-6.
15. Gerhartz HH, Engelhard M, Meusers P, Brittinger G, Wilmanns W, Schlinok G, Mueller P, Huhn D, Musch R, Siegert W, Gerhartz D, Hartlapp JH, Thiel E, Huber C, Peschl C, Spann W, Emmerich B, Schadek C, Westerhausen M, Pees HW, Radtke H, Engert A, Terhardt E, Schick H, Binder T, Fuchs R, Hasford I, Brandmeier R, Stern AC, Jones TC, Ehrlich HJ, Stein H, Parwaresch M, Tiemann M, Lennert K. Randomized, double-blind, placebo-controlled phase III study of recombinant human granulocyte-macrophage colony stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993; 82: 2329-39
16. Schriber JR, Negrin RS, Chao NJ, Long GD, Horning SJ, Blume KG. The efficacy of granulocyte colony stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow. Leukemia 1993; 7: 1491-5.
17. Bolwell BJ, Fishleder A, Andresen SW, Lichtin AE, Koo A, Yanssens T, Burwell R, Baucco P, Green R. G-CSF primed peripheral Wood progenitor cells in autologous bone marrow transplantation: parameters affcting bone marrow engrafment. Bone Marrow Transplant 1993; 12: 609-14.
18. Chao NJ, Schriber JR, Long GD, Negrin RS, Catolico M, Brown BW, Miller LL, Blume KG. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 1994; 83: 2823-8.
19. Ardizzoni A, Venturini M, Sertoli MR, Giannessi PG, Brema F, Danova M, Testore F, Mariani GL, Pennucci MC, Queirolo P, Silvestro S, Bruzzi P Lionetto R, Latini F, Rosso R. Granulocyte-macrophage colony stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy a randomised study in patients with advanced breast cancer. Br J Cancer. 1994; 69: 385-91.
20. Kritz A, Crown TP, Motzer RJ, Reich LM, Heller G, Moore MP, Hamilton N, Yao TJ, Heelan RT, Schneider JG, Moore MAS, McCormick B, Gilewski TA, O'Reilly RJ, Gulati SC, Norton L. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony stimulating factor. A randomized trial. Cancer 1993; 71. 2515-21.
21. Gulati SC, Bennett CL. Granulocyte-macrophage colony stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Int Med 1992; 116: 177-82.
22. De Vries EGE, Biesma D, Willemse PHB, Mulder NH, Stern AC, Aalders JG, Vellenga E. A double-blind placebo-controlled study with granulocyte-macrophage colony stimulating factor during chemotherapy for ovarian carcinoma. Cancer Research, 1991; 51: 116-22.
23. Neumunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, Onetto N, Gillis S, Oette D, Gold M, Buckner D, Hansen JA, Ritz J, Appelbaum FR, Armitage JO, Nadler LM. Recombinant human granulocyte-macrophage colony stimulating factor after bone marrow transplantation for lymphoid cancer N Engl J Med 1991; 324: 1773-8.
24. De Witte T, Vreugdenhil G, Schattanberg A. Prolonged administration of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) after T-cell depleted allogeneic bone marrow transplantation. Transplant Proceed 1993; 25: 57-60.
25. De Witte T, Gratwohl A, Van der Lely N, Bacigalupo A, Stern AC, Speck B, Schattenberg A, Nissen C, Gluckman E, Fibbe WE. Recombinant human granulocyte-macrophage colony stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T cell-depleted bone marrow transplantation. Blood 1992; 79: 1359-65.
26. Advani R, Chao NJ, Homing SJ, Blume KG, Ahn DK, Lamborn KR, Fleming NC, Bonnem EM, Greenberg PL. Granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann Int Med 1992; 116: 183-9.
27. Gore SD, Donnenberg AD, Zehnbauer BA, Weng LJ, Burke PJ. Granulocyte-macrophage colony stimulating factor (GM-CSF) given concurrently with induction therapy for acute myelogenous leukemia (AML) augments the syndrome of T-lymphocyte recovery. Leukemia 1994; 8: 409-19.
28. Powles R, Smith C, Milan S, Treleaven J, Millar J, McElwain T, Gordon-Smith E, Milliken S, Tiley C. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukemia: double-blind, placebo-controlled trial. Lancet 1990; 336: 1417-20.
29. Eastridge BJ, Lefor AT. Complications of indwelling venous access devices in cancer patients. J Clin Oncol 1995; 13: 233-38.
30. Shimoda K, Okamura S, Inaba S, Okamura T, Ohga S, Ueda K, Niho Y. Granulocyte colony-stimulating factor and platelet aggregation. Lancet 1993; 341: 633.
31. Rivera J, Zuazu I, Sanchez MI, Rosillo MC, Arribas F, Heras I, Moraleda JM, Vicente V. Effect of G-CSF on the haemostatic system. Thromb Haemostas 1994; 71: 804-5.
32. Gasson JC, Weisbart RH, Kaufman SE, Clark SC, Golde DW. Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. Science 1984; 226: 1339-42.
33. Arnaout MA, Wang EA, Clark SC, Sieff CA. Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins as mature granulocyte. J Clin Invest 1986; 78: 597-601.